Theriva Biologics, Inc. (TOVX)

Market Cap	2.86M
Revenue (ttm)	n/a
Net Income (ttm)	-26.69M
Shares Out	2.27M
EPS (ttm)	-32.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	57,395
Open	1.290
Previous Close	1.260
Day's Range	1.250 - 1.318
52-Week Range	1.220 - 17.000
Beta	1.34
Analysts	Strong Buy
Price Target	6.00 (+376.19%)
Earnings Date	Nov 12, 2024

About TOVX

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors. It also de...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 26, 2006
• Employees: 22
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: TOVX
• Website: https://therivabio.com

Analyst Forecast

According to one analyst, the rating for TOVX stock is "Strong Buy" and the 12-month stock price forecast is $6.0.

Price Target

$6.0

(376.19% upside)

Analyst Consensus: Strong Buy